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The residual drugs, drug bioconjugates, and their metabolites,
mostly from human and veterinary usage, are routinely flushed
down the drain, and enter wastewater treatment plants (WWTP).
Increasing population, excessive use of allopathic medicine,
continual introduction of novel drugs, and existing inefficient
wastewater treatment processes result in the discharge of
large volumes of pharmaceuticals and their metabolites from
the WWTPs into the environment. The effluent from the
WWTPs globally contaminate ~25% of rivers and the lakes.
Pharmaceuticals in the environment, as contaminants of
emerging concerns, behave as pseudo-persistent despite their
relatively short environmental half-lives in the environment.
Therefore, residual levels of pharmaceuticals in the environment
not only pose a threat to the wildlife but also affect human health
through contaminated food and drinking water. This chapter
highlights WWTPs as point-sources of their environmental
emissions and various effects on the aquatic and terrestrial
ecosystem.
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Introduction
Pharmaceuticals are typically designed to retain their chemical identities long
enough after administration for their targeted therapeutic action in the human
body (1). Administered drugs are excreted as either unchanged parent drugs
and/or conjugated forms (such as glucuronides and glycines) or as metabolites.
Pharmaceuticals, down-the-drain contaminants of emerging concern, eventually
reach wastewater treatment plants (WWTPs). Existing wastewater treatment
processes are incapable of complete removal of pharmaceutical compounds (1,
2); therefore, discharge of WWTP effluents and sewage sludge are considered as
the point sources of environmental contamination from drugs (3, 4).
There were 14,591 publicly owned WWTPs in the U.S.A. serving 226.4
million people in 2012 (5). In the U.S.A., thousands of prescribed and
over-the-counter as well as illicit drugs are discharged annually into the
environment through ~35300 million gallons of wastewater, >8 million of dry
biosolids, and ~500 million tons of animal manure (6–8). Many different classes
of pharmaceuticals including psychoactives, antihypertensives, analgesics,
antibiotics as well as illicit drugs and artificial sweeteners were reported in
wastewater (1, 9–11), sewage sludge (9, 12), receiving waters (13), and drinking
water (14) in the U.S.A..
Understanding the overall fate, distribution, and short and long-term effects of
environmental exposure of pharmaceuticals is important to minimize exposure and
to protect the aquatic ecosystem and human health. It is particularly critical in the
fast-growing southwest region of the U.S.A. where reclaimed water consumption
is being commonly practiced (15). Pharmaceuticals in the environment have the
potential to bioaccumulate (16); for example, a report found that the diclofenac
and gemfibrozil were bioaccumulated by biofilm and aquatic invertebrates
(17). However, very little is known about the potential ecological risks of most
pharmaceuticals and their metabolites/transformed products in the environment
(18). Pharmaceuticals discharged from WWTPs not only pose a direct ecological
risk, but can also turn onto the precursors of hazardous substances. For
instance, methadone forms N-nitrosodimethylamine, a carcinogenic disinfectant
byproduct, during the drinking water treatment process (19). Overall, very little
is known about the potential chronic effects of pharmaceutical contaminants
on environmental biota and human health, particularly with the exposure to a
“cocktail” of pharmaceutical contaminants (20). In this chapter, we discuss the
occurrence and mass loading of pharmaceuticals into WWTPs, their removal,
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Mass Loading of Pharmaceuticals into the WWTPs
Wastewater Influent
Various classes of pharmaceuticals including antibiotics, analgesics,
antihypertensives, illicit drugs, and psychoactives were reported at ng/L to µg/L
levels that enter WWTPs (Table 1 and Figure 1) (1, 4, 7, 9–11, 20–33). WWTPs in
the U.S.A. typically treat millions of gallons of domestic and/or industrial sewage
every day (34); a WWTP that treats 25 MGD wastewater would daily receive
milligrams to several grams of the individual pharmaceutical compounds. These
statistics appear daunting when thousands of prescription, over-the-counter, illicit,
veterinary drugs, their metabolites, and their conjugates enter into the WWTPs.
Pharmaceutical prioritization for the research on environmental occurrence
as well as their effects on the environment and human health should subject to
geographical regions, climates, demographics, and cultural backgrounds (18).
In 2011, 262.5 million of antibiotic prescriptions were dispensed in the U.S.A.,
that equivalents to >5 prescriptions to every 6 people (35). Azithromycin,
sulfamethoxazole, and trimethoprim are among the top prescribed antibiotics
in the U.S.A. (36); and are also the most frequently detected antibiotics in
wastewater (1, 22–25). Sulfamethoxazole and trimethoprim were loaded at 0.71
kg/d and 0.39 kg/d, respectively, into a WWTP serving ~650,000 people in Las
Vegas, NV, U.S.A. (22). Diphenhydramine, a first generation antiallergenic drug,
was found at 530 ng/L of diphenhydramine in wastewater influent during elevated
seasonal allergies in Texas, U.S.A. (24).
A recent large-scale study (from 50 large WWTPs from 20 states in the
U.S.A. that treat ~17% of total wastewater produced in the U.S.A.) found
antihypertensives and antipsychotics in wastewater more frequently at higher
concentrations than other classes of prioritized pharmaceuticals (7). Psychoactives
are among the most widely prescribed pharmaceuticals globally (37). In the
U.S.A., the total usage of psychoactive pharmaceuticals increased from 1998 to
2008 by 78% (38), and were the top-selling classes of prescription medications,
with $14.6 billion in sales in 2009 (39). Twenty-two pharmaceuticals listed
in Table 1 are among the top 100 prescribed pharmaceuticals in the U.S.A.
in 2011 (www.rxlist.com). A wide range of psychoactive drugs including
antischizophrenics, sedatives-hypnotics-anxiolytics, and antidepressants was
found in wastewater influent in the U.S.A. (Table 1). The mass loading of
aripiprazole, the most prescribed drug in the U.S.A. (www.drugs.com), to
a WWTP was found to be 6.46 mg/d/1000 people in NY (9). Alprazolam,
quetiapine, sertraline, lorazepam, fluoxetine, bupropion were the top psychoactive
drugs sold in the U.S.A. in 2013 (www.psycentral.com); and were found at a
loading of 1.66-78.9mg/d/1000 people in aWWTP inNY (9). Carbamazepine and
selective serotonin reuptake inhibitors (SSRI) such as sertraline, citalopram, and
fluoxetine were the most frequently detected antipsychotic drugs in wastewater in
the U.S.A. (3, 9, 22, 24, 25, 40). Venlafaxine was found at 0.93 µg/L in a WWTP
serving 1.8 million people and ~800 industries in St. Paul, MN that equivalents
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Table 1. Occurrence of pharmaceuticals in wastewater influent, effluent, and sludge in the U.S.A.
Influent Effluent SludgeAnalytes
Concentration (ng/L) Concentration (ng/L) Concentration (ng/g dw)
Psychoactives
Aripiprazole 5.43 (9), 5.58 (9) 1.69 (9), 10.3 (9) 16.8 (9), 115 (9)
Dehydro-aripiprazole - - 1.49 (9), 2.93 (9)
Quetiapine 15.5 (9), 24.4 (9) 0.98 (9), 4.60 (9) 17.7 (9), 21.1 (9)
Nor-quetiapine 66.1 (9), 71.0 (9) 74.3 (9), 82.3 (9) 133 (9), 196 (9)
Lorazepam 16.2 (9), 20.3 (9) 64.2 (9), 78.4 (9) 0.26 (9)
Alprazolam 5.89 (9), 6.24 (9) 4.59 (9), 6.20 (9) 0.28 (9), 0.61 (9), 1.56 (21)
α-hydroxy alprazolam 17.4 (9), 21.4 (9) 9.2 (9), 12.7 (9) 0.37 (9), 1.43 (9)
Diazepam 3.38 (9), 3.79 (9) 1.73 (9), 2.58 (9), 3.70 (22) 0.48 (9)
Oxydiazepam 6.52 (9), 8.43 (9) 7.72 (9), 9.87 (9) 0.86 (9), 1.60 (9)
Nordiazepam 4.04 (9), 5.30 (9) 3.69 (9), 4.53 (9) 0.96 (9), 1.08 (9)
Carbamazepine 145 (9), 241 (9), 232 (22), 100 (23)
147.5 (24), 137 (25), 115 (26), 102 (27)
310 (9), 268 (9), 187 (22), 65 (23), 119.5
(28), 156 (25), 97 (7), 21.3 (26), 175 (27)
83.1 (9), 118 (9), 66.5 (26)
Sertraline 43.1 (9), 80.8 (9), 60 (4) 82.8 (9), 24.5 (9), 55.2 (4), 21 (7) 862 (9), 1490 (9), 458 (21)
Norsertraline 65.3 (9), 71.1 (9), 14.3 (4) 54.4 (9), 16.4 (9), 37.5 (4), 9.9 (7) 394 (9), 688 (9)
Venlafaxine 336 (9), 415 (9), 930 (4) 480 (9), 339 (9), 873 (4) 84.2 (9), 129 (9)
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Influent Effluent SludgeAnalytes
Concentration (ng/L) Concentration (ng/L) Concentration (ng/g dw)
Citalopram 59.4 (9), 133 (9), 78.9 (4) 280 (9), 150 (9), 125 (4) 170 (9), 283 (9)
Desacetyl citalopram 12.8 (9), 55.4 (9) 79.3 (9), 118 (9) 130 (9), 222 (9)
Paroxetine 10.5 (4) 15.8 (4) 41.6 (21)
Fluoxetine 27.1 (4), 17 (22), 600 (23), 45.3 (4), 25 (22), 560 (23), 8.6 (7), 20 (27),
60 (29), 56 (29)
-
Norfluoxetine 14.2 (4), 9.9 (22) 13.6 (4), 3.9 (22), 7.1 (7), 20 (29), 26 (29) -
Anti-hypertensions
Atenolol 1220 (9), 606 (9), 3060 (22), 1172.5
(24)
594 (9), 426 (9), 879 (22), 940 (7), 281 (27) 23.0 (9), 27.6 (9)
Propranolol 24.5 (9), 24.1 (9), 7.5 (24) 74.2 (9), 82.2 (9), 33 (7) 83.3 (9), 49.7 (9), 107.4 (21)
Diltiazem 105 (9), 168 (9), 1019.4 (24) 194 (9), 53 (23), 85 (7) 48.5 (9), 61.9 (9)
Desacetyl diltiazem 473 (9), 483 (9) 294 (9), 327 (9) 84.9 (9), 179 (9), 7.4 (21)
Verapamil 7.30 (9), 18.5 (9) 38.5 (9), 49.2 (23), 26 (7) 218 (9), 170 (9), 551.4 (21)
Nor-verapamil 8.88 (9), 14.8 (9) 8.29 (9), 20.3 (9), 5.8 (7) 385 (9), 175 (9), 458 (21)
Analgesics
Hydrocodone 70 (9), 130 (30), 210 (30), 13 (30), 80
(30), 14 (30), 30 (30),
8.6 (23), 22 (7), 910 (20), 330 (20) 21.7 (21)
Oxycodone 80 (30), 210 (30), 58 (30), 15 (30), 220
(30), 29 (30)
53 (7) 157 (21)
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Table 1. (Continued). Occurrence of pharmaceuticals in wastewater influent, effluent, and sludge in the U.S.A.
Influent Effluent SludgeAnalytes
Concentration (ng/L) Concentration (ng/L) Concentration (ng/g dw)
Diclofenac 116 (22), 104.75 (24), 277 (22), 83 (27) 12 (26), 83 (27) 48.4 (26)
Naproxen 22500 (22), 35700 (22), 11772 (27) 30.0 (26), 13 (27) 19.1 (26)
Acetaminophen 6100 (23), 18775 (24), 45726 (27),
99498 (29), 113281 (29)
860 (23), 79 (7), 354 (29), 152 (29) -
Ibuprofen 22300 (26), 13481 (27), 24317 (29),
24033 (29)
460 (7), 55.8 (22), 9 (27), 928 (29), 2600
(29)
109 (22)
Codeine 170 (23), 205 (24) 170 (23)
Antihistamine
Diphenhydramine 462 (9), 227 (9), 367.5 (24) 194 (9), 85.7 (9), 588.8 (28) 293 (9), 444 (9)
2-(diphenylmethoxy) acetic acid 3.70 (9), 3.79 (9) 4.14 (9), 4.50 (9) -
Antiplatelet
Clopidogrel 31.4 (9), 35.5 (9) 21.8 (9), 23.7 (9) 29.0 (9), 31.4 (9)
Clopidogrel carboxylic acid 124 (9), 160 (9) 116 (9), 194 (9) 2.26 (9), 3.24 (9)
Anticholesterolemic
Gemfibrozil 4770 (22), 1500 (24), 934 (25), 4670
(25), 791 (27)
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Influent Effluent SludgeAnalytes
Concentration (ng/L) Concentration (ng/L) Concentration (ng/g dw)
Sulfamethoxazole 2060 (22), 360 (23), 2625 (24), 1786
(25), 2252 (27)
5.0 (22), 140 (23), 141.4 (28), 304 (25),
910 (7), 313 (27)
-
Trimethoprim 1140 (22), 300 (23), 417.5 (24), 913
(27)
120 (23), 170 (7), 115 (27) -
Azithromycin 28.2 (1) 690.4 (28), 15 (31), 66 (32), 17 (25), 56




Cocaine 74.2 (10), 77.6 (10), 35 (30), 230 (30),
56 (30), 66 (30), 72 (30), 10 (30), 860
(30), 769 (32)
1.75 (10) 3.6 (21), 1.7 (10), 4.48 (10)
Benzoylecgonine 6100,(33) 71023 (10), 1793 (10), 2800
(30), 2100 (30), 370 (30), 620 (30), 420
(30), 110 (30), 1500 (30), 1573 (32)
98.1 (10), 18.5 (10) 1.05 (10)
Norcocaine 2.92 (10), 5.64 (10), 15 (30), 9 (30), 4
(30), 50 (30), 17.9 (32)
1.02 (10), 5.07 (10) -
Cocaethylene 3.94 (10), 4.84 (10) - -
Amphetamine 92.3 (10), 92.1 (10), 220 (30), 550 (30),
80 (30), 120 (30), 250 (30), 90 (30), 130
(30), 309 (32)
3.5 (7) -
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Table 1. (Continued). Occurrence of pharmaceuticals in wastewater influent, effluent, and sludge in the U.S.A.
Influent Effluent SludgeAnalytes
Concentration (ng/L) Concentration (ng/L) Concentration (ng/g dw)
Methamphetamine 3.82 (10), 6.22 (10), 920 (30), 2000
(30), 10 (30), 920 (30), 150 (30), 1494
(32), 25.3 (1)
350.1 (28), 4.98 (10), 22.3 (10), 13 (31),
0.8 (32), 355 (20), 230 (20), 270 (20), 227
(20), 318 (20), 190 (20), 570 (20), 110 (20)
-
Morphine 158 (10), 203 (10), 647 (32) 33.9 (10) 18.4 (10), 21.6 (10)
Methadone 5.41 (10), 20.6 (10), 33 (30), 59 (30),
4.9 (30), 16 (30), 62 (30), 14 (30), 47
(30)
17.3 (10), 18.2 (10) 13.9 (10), 20.3 (10)
EDDP 22.6 (10), 45.6 (10) 38.2 (10), 110 (10) 21.5 (10), 49.8 (10)
MDMA 10.1 (10), 25.4 (10), 70 (30), 30 (30),
2.7 (30), 10 (30), 3.5 (30), 185 (32)
2.88 (10), 23.2 (10), 0.5 (31), 96 (20) 3.95 (10)
MDEA 2.33 (10), 3.29 (10) 0.27 (10), 1.12 (10) 0.68 (10)
MDA 118 (10), 491 (10), 6 (30), 2 (30), 7 (30),
45.5 (32)
12.8 (10), 34.4 (10) 23.2 (10), 42.4 (10)
Artificial Sweeteners
Sucralose 47500 (24), 33000 (11), 25900 (11) 20500 (11), 38800 (11) 423 (11), 651 (11)
Saccharin 13800 (11), 16400 (11) 420 (11), 2340 (11) 180 (11), 286 (11)
Aspartame 80 (11), 180 (11) 80 (11), 140 (11) 80 (11), 448 (11)
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Influent Effluent SludgeAnalytes
Concentration (ng/L) Concentration (ng/L) Concentration (ng/g dw)
Caffeine 42000 (23), 27700 (10), 26900 (10),
5700 (30), 120000 (30), 14979 (27),
66400 (29), 82882 (29)
15200 (23), 535.3 (28), 37.9 (10), 129 (10) -
Paraxanthine 55000 (23),14700 (10), 9650 (10) 25000 (23), 112 (28), 39.4 (10), 16.4 (10) -
Nicotine 17000 (23), 3670 (10), 3800 (10), 1177
(27)
21000 (23), 27.5 (10), 19.6 (10) -
Cotinine 1980 (10),1430 (10), 2000 (30), 2700
(30), 1461 (29)
14.1 (10), 34 (10) -
In a WWTP Murray, KY serving 15100 people and treats 5 MGD (1); In a WWTP in St. Paul, MN serving 1.8 M people and ~800 industries (4); In 50
WWTPs from 20 States across the U.S.A. served over 46 M people and treats 6000 MGD (7); In In 2 WWTPs in Albany, NY serving 15,000 and 100,000
people (9); In 2 WWTPs in Albany, NY serving 15,000 and 100,000 people (10); In 2 WWTPs in Albany, NY serving 15,000 and 100,000 people (11); In 10
WWTPs in AZ, CO, NV, and UT (20); In 94 WWTPs from 32 states and the DC under USEPA’s National Sewage Sludge Survey Program (21); In a WWTPs in
Las Vegas, NV serving 650,000 people and treats 91 MGD (22); In a WWTP in Jamaica Bay, NY that treats 81 MGD (23); In a WWTP in Waco, TX serving
~100,000 people and treats ~25 MGD wastewater inflow (24); In 3 WWTPs in Mississippi serving 26000 to 299000 people and treats 3.5-47 MGD (25); In 5
WWTPs in Southern California serving 100000-195000 people and treat 42-68 MGD (26); In 2 WWTPs in Southeast U.S.A. 100000-195000 people and treat
20 and 36 MGD (27); In a WWTP in Omaha, NE serving population of 419,545 and treats 27.2 MGD wastewater inflow (28); In 2 WWTPs in Charleston,
SC treating 20 and 5.1 MGD (29); In 7 WWTPs across the U.S.A. serving population ranged from 27300 to 841000 (30); In 3 WWTPs in NV, UT, and SC
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Figure 1. Concentration of pharmaceuticals and their select metabolites in
wastewater influents from the WWTPs in the U.S.A.
The regional distribution patterns of the select pharmaceuticals are different in
the U.S.A. (41). Despite the relatively higher usage of oxycodone in the Northeast
and that of hydrocodone in the Midwest, South, and the Western U.S.A. among
major narcotic analgesics (41); Chiaia et al. (30) reported higher concentrations
of oxycodone than hydrocodone across the U.S.A.. The usage and availability
of analgesics in prescription and over-the-counter forms are increasing; aggregate
production quotas of hydrocodone and oxycodone in the U.S.A. was increased
by ~300% to ~90,000 kg and ~55,000 kg, respectively, from 2000 to 2010 (42).
Acetaminophen was reported highest (61.0 µg/L) in wastewater influent from a
WWTP in NY that treats 81 MGD (23) that is equivalent to a mass loading of
18.7 kg/d of acetaminophen into the WWTP. Similarly, 7.75 kg/d mass loading
of naproxen into a municipal WWTP serving ~650,000 people in Las Vegas, NV,
U.S.A. was found (22). The hydrocodone-acetaminophen combinationmedication
was not only the most frequent opioid analgesic prescribed in the United States but
was also the overall top prescribed drug with 3995.2 million prescriptions being
dispensed in 2010 (43).
The United Nations Office on Drugs and Crime (UNODC) estimated that
there were over 165-315 million illicit-drug users globally (44); and 9.4% of
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Cocaine is one of the major illicit drugs second only to cannabis in the U.S.A.;
and 94 tons of cocaine (~10.5% of the total global production) seizures were
reported in 2011 (44). Cocaine was found in 93% of wastewater influent samples
(10). Individual illicit drugs including cocaine, methamphetamine, morphine,
methadone, MDMA, and their metabolites were loaded at 0.07 to 149 g/d into the
WWTPs in NY (serving ~100,000 people). Subedi and Kannan (10) also utilized
the concentrations of illicit drugs in influent, so-called sewage epidemiology, to
estimate community usage of illicit drugs. The consumption rate of illicit drugs
in Albany, NY ranged from 1.67 to 3510 mg/d/1000 people. An estimate of daily
consumption of cocaine in Lubbock, TX was 1152 ± 147 g; young adults (15-34
years) alone consume 13.1 ± 1.7 g/d/1000 individuals in Lubbock, TX (33).
Methamphetamine users in the U.S.A. increased by 68.6% to 595,000 users from
2010 to 2013 (45); and several studies reported methamphetamine in influent
across the U.S.A. (1, 10, 25, 30).
With the availability of isotopically labeled standards of parent drugs and
their metabolites, as well as the recent analytical improvements capable of
simultaneous analysis of pharmaceuticals and their metabolites, fate studies
are increasingly determining metabolites along with their parent analogs. The
ratio of degradates/metabolites to their parent compounds in wastewater can
provide additional sources of contaminants. For instance, the metabolite to parent
drug ratio for sertraline and fluoxetine of <1 in influent suggested either direct
disposal of unused parent drug in wastewater or transformation/degradation of
conjugated forms of drug into their parent drug during wastewater treatment
process (3, 4). Moreover, drug metabolites such as norfluoxetine are as
pharmacologically active as the parent fluoxetine. The concentration of
clopidogrel carboxylic acid, a metabolite of clopidogrel, was ~4 times higher
than its parent drug (9) and methadone in influent was ~3 times lower than its
metabolite [(2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)] (10).
The overall concentrations of a parent drug and its transformed product/metabolite
provide a better estimate of the total mass loading of a drug into the WWTPs.
It is also important to recognize potential seasonal variations of
pharmaceutical loading into theWWTP for the evaluation of wastewater treatment
process and overall performance of WWTPs. For example, a load of antipyretics
such as ibuprofen can be higher in winter while that of an antihistamine such as
diphenhydramine can be relatively higher in summer due to their increased usage
in respective seasons (7). Cocaine consumption on weekends was found higher
than on weekdays while monitoring a reclamation plant for a 5-month period
in Lubbock, TX using sewage epidemiology (33). Moreover, special events in
WWTP network coverage such as sporting events can increase the mass loading
of prescribed and illicit drugs into the WWTPs (32).
Suspended Particulate Matter
Very few studies of the fate of pharmaceuticals in WWTPs have incorporated
the pharmaceutical concentrations in suspended particulate matter (SPM) to
estimate the mass loading of pharmaceuticals into the WWTPs in the U.S.A.
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dissolved fraction of pharmaceuticals; which can be near an accurate mass
loading of the highly water soluble pharmaceuticals to the WWTPs. However,
select parent drugs and their metabolites having a relatively higher organic
carbon-water partitioning coefficient (Koc) can significantly partition onto SPM.
For example, the estimation of a mass loading of methadone based only on
the aqueous concentration of methadone and its metabolite (EDDP; log Koc =
5.673) in wastewater can underestimate the total methadone loading by 40% (10).
Similarly, a ~50.4% mass loading of aspartame to the WWTP was found to sorb
in SPM unlike sucralose, saccharin, and acesulfame, which have >90% of their
mass loading in filtered wastewater (11).
Removal of Pharmaceuticals from WWTPs
Wastewater treatment processes in the U.S.A. typically is comprised
of preliminary treatment (screening and grit removal), primary treatment
(sedimentation), and secondary treatment (biological treatments using activated
sludge/trickling filters/facultative lagoon). Secondary treatment is a national
standard of the U.S.A. to discharge treated wastewater to surface water (46).
While conventional activated sludge (CAS) is the most common biological
treatment system in use, advanced or tertiary treatment may be required at specific
sites to comply with the regulations set to protect human health and the ecosystem.
The dominant mechanism of removal of pharmaceuticals having higher sorption
coefficient (Kd > 300 kg L-1) is the adsorption to sludge whereas more acidic drugs
including most of the pharmaceutical metabolites undergo biodegradation (47).
The removal of pharmaceutical from WWTPs depends on the physiochemical
properties of the drug, treatment process, capacity, microbial environment, season
(temperature), precipitation, pH, etc. However, the removal of pharmaceuticals
from WWTPs is barely complete with the existing conventional wastewater
treatments in use despite the multi-step treatments (2).
Overall, inconsistent removal efficiencies of most of the pharmaceuticals
were reported from the WWTPs in the U.S.A. (Figure 2) (1, 4, 9, 23, 25–27, 29).
Select psychoactives such as venlafaxine, fluoxetine, citalopram, carbamazepine,
alprazolam, and lorazepam had very low (usually <25%) removal from WWTPs
(4, 9). Complex removal mechanisms during wastewater treatment can be
responsible for no or negative removal of select pharmaceuticals such as
deconjugation of carbamazepine glucuronide (48), deconjugation of morphine
glucuronide (10), and polyhalogenated structural rigidity of sucralose (11, 24).
Unlike psychoactives, analgesics such as hydrocodone, diclofenac, naproxen,
acetaminophen, and ibuprofen were significantly (57-100%) removed from
WWTPs employing CAS in the U.S.A. (22, 23, 26, 27, 29). Azithromycin
was barely removed from a WWTP in KY(1) but 60-100% mass loading of
sulfamethoxazole and trimethoprim were removed from WWTPs in different
states in the U.S.A. (22, 23, 25, 27). Similarly, ~70-90% mass loading of cocaine,
benzoylecgonine, amphetamine, and MDA were removed from WWTPs in NY
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Figure 2. Removal efficiency of pharmaceuticals from WWTPs in the U.S.A.
Environmental Emission of Pharmaceuticals from WWTPs
Wastewater Effluent
Treated wastewater effluent is a point source of pharmaceuticals into the
aquatic environment (3, 4). Typically, the effluent discharge is a “cocktail” of
unchanged parent drugs, metabolites, their conjugates, and potentially several
other WWTP-derived transformed products (Table 1, Figure 3) (1, 4, 7, 9, 10,
20, 22, 23, 25–29, 31, 32). Pharmaceutical discharge into the environment
was apparent as early as 1977 when 28.69 kg of salicylic acid was reported
to discharge daily to the Missouri River in Kansas City through wastewater
effluent from a WWTP that served 600,000 people treating 300 MLD wastewater
(49). After more than two decades, ng/L to µg/L levels of psychoactives,
antihypertensives, antibiotics, analgesics, and their select metabolites are reported
in 139 sewage-impacted streams in 32 states in the U.S.A. (13). Above-mentioned
pharmaceuticals were also found at ng/L in Boulder Basin of Lake Mead,
a source of drinking water for the Las Vegas Metropolitan area (22) and in
19 drinking water utilities across the U.S.A. (14). Once discharged into the
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in surface water (3); venlafaxine was found as high as 102 ng/L even at 8.4
km downstream from a single-source effluent-impacted streams. Recently,
several pharmaceuticals including carbamazepine, atenolol, sulfamethoxazole,
diphenhydramine, gemfibrozil, and cocaine, were found in near shore sites of San
Francisco Bay, CA (50) and Muir Beach to Monterey Bay, U.S.A. (51).
Figure 3. Concentration of pharmaceuticals and their select metabolites in
wastewater effluents from the WWTPs in the U.S.A.
Psychoactives and antihypertensives were the most frequently detected
among 63 pharmaceuticals at highest concentrations in effluents from 50
large WWTPs across the U.S.A. (7). Total discharge of 16 psychoactive
pharmaceuticals and their select metabolites from a WWTP in Albany, NY was
found at 1542 mg/d/1000 inhabitants, which is equivalent to an annual discharge
of 56.3 kg psychoactives into the river (9). Annual discharge of azithromycin and
methamphetamine from a WWTP to receiving water in Nevada was 1-4 kg and
0.05-0.11 kg, respectively, whereas that of MDMA in South Carolina was 0.02
kg (31). However, 6.5 kg of illicit drugs including cocaine, methamphetamine,
morphine, methadone, MDMA, and their metabolites were discharged into
the river from a WWTP in NY (10). The pharmaceutical discharge through
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earlier for influent. The concentrations of pharmaceuticals in effluent during
winter can be higher than in summer due to relatively higher human-consumption
of drugs and inefficient biodegradation of drugs in winter (26).
Wastewater contamination in the environment has shown to be traceable
with select chemical tracers. Chemical traceability of wastewater contamination
depends on its dynamic reserve (i.e. the ratio between highest measured
concentration and its method detection limit) and the detection frequency.
High dynamic reserve and detection frequency of contaminants qualify for the
contaminant’s stability and potential of being detected under highly diluted
conditions (9). Due to their ubiquitous occurrence and persistence, sucralose (52),
acesulfame (53), and caffeine (54) were used as chemical tracers of wastewater
contamination. Benotti et al. (14) also suggested atenolol and trimethoprim as
indicator compounds for wastewater contamination and to estimate the efficacy
of wastewater treatment.
Sewage Sludge
About 6.5 million metric tons of dry sewage sludge is produced annually
in the U.S.A., and >60% of treated sewage sludge is applied to land in the
U.S.A. in 2004 (55). The US EPA also estimated that ~0.1% of agricultural
land in the U.S.A. is annually applied with biosolids (56). The U.S.A. regulates
the use or disposal of sewage sludge through the Code of Federal Regulation
Title 40, Part 503; the US EPA currently has establishes regulatory limits for
select toxic chemical contaminants; however, limits are not yet established
for pharmaceuticals. Pharmaceuticals were the dominant class of organics
determined, second to alkylphenols and their ethoxylates, in National Sewage
Sludge Repository samples that encompassed digested municipal sewage samples
from 164 WWTPs across the U.S.A. (57). More frequent large-scale screening
to identify and prioritize the potential toxic pharmaceuticals is warranted. In a
nationwide study determining pharmaceuticals in composite biosolid samples
from 94 WWTPs in 32 States and the District of Columbia in the U.S.A.
(Figure 4), it was estimated that 210-250 tons of 72 pharmaceuticals including
psychoactives, antihypertensives, and antibiotics reside annually in US soils from
biosolids land application (12).
Select pharmaceuticals and their metabolites preferentially adsorb onto
the sludge, which depends primarily on their organic carbon-water partitioning
coefficient (Koc) values. The environmental discharge of sertraline, nor-sertraline
(a metabolite of sertraline), verapamil, and norverapamil through sewage sludge
was significantly higher than other psychoactives and antihypertensives (9).
However, the partitioning kinetics can vary with seasons; antibiotics’ partitioning
was higher in winter and lowest in autumn (58).
Previously the fraction of contaminants partitioned into sewage sludge
was considered as “removed”; however, contaminants cannot be considered
“removed” unless eliminated from treated sludge prior to their discharge or
land-application (37). Pharmaceuticals can be bioavailable in the soil for an
extended period after sludge application; norfluoxetine was measured at 0.29-0.32
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many studies report the uptake of sludge-derived contaminants by plants (60) and
soil-dwelling organisms (6). Nevertheless, the discharged pharmaceuticals can
be deposited at the bed-sediments (3) or bioaccumulated by the aquatic organism
(16, 61, 62).
Figure 4. Rank order of Mean concentrations of Pharmaceuticals in composites
of a total of 110 biosolid samples from 94 WWTPs in 32 States and the District
of Columbia in the U.S.A. Newly detected pharmaceuticals are shown in darker
hue. (Reproduced with permission from Ref. (12): Copyright 2010 Elsevier).
Effect of Pharmaceuticals in Environment
Pharmaceuticals in the environment are relatively short-lived compared to
classic persistent organic pollutants; however, daily used of pharmaceuticals
and our modern sanitary practices result in their continual discharge into the
environment, making pharmaceuticals pseudo-persistent contaminants in the
environment (2). Therefore, aquatic organisms are exposed over their lifetime
to a “cocktail” of discharged pharmaceuticals, their conjugates, and metabolites.
Pharmaceuticals have been shown to accumulate in lettuce (Lactuca sativa) (63),
periphyton and snails (64), in mussels (65), fish tissues (61), and sharks (66).
Toxicological consequences of chronic exposure of a pharmaceutical blend
in the environment are likely more appropriate to consider but have not been
implicit yet (14). However, low-level exposure to an individual drug over time
has caused physiological and behavioral alternations. For example, venlafaxine,
one of the depressants found at µg/L levels in the environment, significantly
decreased serotonin concentration in the fish brain (67). Similarly, diazepam
altered the swimming behavior of zebrafish embryos exposed to 235 ng/L for 14
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of fathead minnow to as high concentration as 13 µg/L. Nevertheless, the
effective environmental effect can be substantial if organisms exposed to multiple
pharmaceuticals with the same modes of action are present in the ecosystem (2).
Typically, risk quotient (RQ), the ratio between the concentration of
pharmaceutical and its predicted no-effect concentration (PNEC), is used to
determine the potential risk associated with the environmental occurrence (69).
A significant ecotoxicological risk (RQ >1) to human health was reported
from a psychoactive in sewage sludge (26), from antibiotics, analgesics,
and antihypertensives in digested sludge (69), and antibiotics in digested
sludge-amended soil (12). Alternatively, the ecological risk associated with the
pharmaceutical exposure in the environment can be estimated by comparing
the effluent concentration of drugs with minimum therapeutic daily dose rate
(Ddmin) or free plasma concentration after therapeutic dose (Cmax). The effluent
concentrations of all 43 individual pharmaceuticals detected from 50 large
WWTPs across the U.S.A. were well below their Ddmin (7). The ratio of the
effluent concentration to the corresponding Cmax was <0.1; however, sertraline
(0.71), propranolol (0.65), and valsartan (0.18) levels suggested the immediate
risks to the fish and other aquatic organisms.
In addition to direct ecological risk, the potential of antibiotic residues in
the environment to emerge as human pathogens resistant to specific antibiotics
has recently been considered a global concern. The global consumption of
antibiotics has increased >30% from 2000 to 2010; the U.S.A. annually produces
>50,000,000 lbs of antibiotics that are extensively used in human therapy and
veterinary (70). Survival of the fittest at the bacterial level of antibiotic-resistant
bacteria (ARBs) depends on the volume of antibiotics used and the patterns of
infectious disease. In the U.S.A., antibiotic resistance annually causes 2 million
infections and 23,000 deaths that cost $20 billion in direct health care and $35
billion of productivity loss (70, 71). In the U.S.A., antibiotics are frequently
detected in wastewater effluent (72) and surface water at ng/L to µg/L levels;
and antibiotics at these concentrations in the environment were reported to
influence the proliferation of ARBs in the environment (73). Moreover, the
biological treatment during wastewater treatment can even increase the ARBs
and antibiotic-resistant genes (ARGs), which are eventually discharged into
the surface water (12). A recent study showed that the ARGs in the river were
significantly correlated with upstream capacities of WWTPs (73). In addition,
pharmaceuticals in the environment not only pose an immediate ecological risk
but can also transform into more toxic substances. For example, methadone can
form a carcinogenic disinfectant byproduct, N-nitrosodimethylamine, during the
drinking water treatment process (19).
Insights and Future Perspectives
Despite thousands of drugs on the market and >30 new drugs annually
approved by US FDA, very few (~100) pharmaceutical contaminants are
reported in the U.S.A.. Some of the most prescribed and sold classes of drugs
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were scarcely reported in the environment. Therefore, the fate studies of a
diverse class of prescribed drugs, illicit drugs, and designer drugs as well as
their environmental emission are critical. As discussed earlier, mass loading
calculations should incorporate the fraction of drugs in SPM while the estimation
of environmental emission should incorporate the fraction partitioned on sewage
sludge. It is particularly important for the pharmaceuticals having relatively
higher solid-liquid partitioning coefficients. Similarly, the mass loading of
pharmaceutical metabolites into the WWTPs can be as high as their parent
drugs while the environmental emission of metabolites of select drugs from
WWTPs has been found more than their parent drugs (9, 10, 37). In addition,
biochemical degradation of pharmaceuticals during wastewater treatment process
should not always be considered as “removal” since they can be transformed
into the hazardous products and/or still have enough biochemical activity to pose
ecological toxicity.
On another hand, pharmaceutical prioritization for the fate and toxicological
investigation should depend on regional usage patterns, sewage treatment
strategies, and the drug’s potential toxicological effects in the environment. For
instance, the number of Klebsiella pneumoniae, antibacterial-resistant bacteria,
infections was increased ~10% from 2008 to 2014 in the U.S.A. while increasing
~100% in India (74), where ~67% patients purchase medication without a
prescription and ~70% of the total sewage produced is discharged into the
environment without any treatment (75). The U.S. Food and Drug Administration
implementing the voluntary plan with industries to phase out concerned antibiotics
in the U.S.A. (76), however, the need-based administration, recycling unused
drugs, and development of next-generation antibacterial drugs are inevitable.
There are very few reports on environmental contamination from
pharmaceuticals discharged from on-site wastewater treatment (septic) systems
despite 25% of the U.S. population being served by the septic systems (77, 78).
Therefore, more investigations on pharmaceutical contamination from septic
systems would reveal their effects in suburban and rural areas. The potential of
pharmaceuticals and illicit drugs to contaminate the sources of drinking water, as
well as their potential of escaping degradation during drinking water treatment
process should be addressed.
There are increasing reports of acute aquatic toxicity from the exposure of
residual levels of pharmaceuticals in the environment (16, 78); however, the
chronic aquatic toxicity and the mechanism-of-action based toxicity studies are
rarely available. The aquatic organism is continually exposed not only to an
environmental cocktail of diverse pharmaceuticals but also to a diverse group
of persistent contaminants. Potential different modes of efficacy including
synergism can exist and would assist to evaluate the mechanism-of-action as well
as mode-of-action based aquatic toxicity. Further evaluation of toxicity associated
with the uptake of WWTP-derived pharmaceuticals from biosolids-applied
farmland is warranted since ~2/3 of the total sewage sludge produced is applied
to farmland in the U.S.A..
Overall, the need for a sustainable solution is becoming increasingly critical
and one of the important challenges of the 21st century, that could somehow
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effects in wildlife and humans. Sustainable solutions for this global problem
require innovative research in this area, that necessitates ample resources
including research funding. Federal and pharmaceutical agencies may consider
funding for novel and innovative ideas that have potential to provide sustainable
and global solutions.
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